Trial Profile
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Aug 2022
Price :
$35
*
At a glance
- Drugs Deucravacitinib (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 12 Aug 2022 Results assessing efficacy of deucravacitinib over 52 weeks in the POETYK PSO-1 and POETYK PSO-2 trials published in the American Journal of Clinical Dermatology
- 13 Jan 2022 Results of post hoc analysis evaluating the effect of deucravacitinib on additional clinical and quality-of-life (QoL) outcomes and assessing the relationship between these outcomes in adults with psoriasis published in the Dermatology and Therapy
- 15 Jun 2019 Results assessing influence of baseline demographics and disease charecteristics on efficacy of BMS-986165 presented at the 20th Annual Congress of the European League Against Rheumatism